Drug Type Autologous CAR-T |
Synonyms SNC 109, SNC109 |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Glioblastoma | Phase 1 | CN | 24 Jun 2022 |